Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410686 | 1.00 | HDAC1 (0.60) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2407610 | 0.90 | HDAC1 (0.58) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2407606 | 0.90 | HDAC1 (0.58) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL212090 | 0.86 | HDAC1 (0.58) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL212089 | 0.86 | HDAC1 (0.58) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2409642 | 0.86 | HDAC1 (0.56) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2495534 | 0.86 | HDAC1 (0.56) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2404792 | 0.84 | HDAC1 (0.48) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2408220 | 0.83 | HDAC1 (0.54) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2493510 | 0.83 | HDAC2 (0.56) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354445-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-01-15 | — | — | US | claimed |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2011-09-01 | — | — | US | claimed |
| EP-2134680-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-12-23 | — | — | EP | claimed |
| WO-2008109994-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-09-18 | — | — | WO | claimed |
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-09-18 | — | — | US | claimed |
| EP-2134680-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-8354445-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-01-15 | — | — | US | disclosed |
| US-8030344-B2 | Such as (S)-2-(Dimethylamino)ethyl-1-(4-(2-aminophenylcarbamoyl)-phenyl)pyrrolidin-3-ylcarbamate for treating cell proliferative disorders | METHYLGENE INC. (CA) | 2011-10-04 | — | — | US | disclosed |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| EP-2134680-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008109994-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC2 5/4885HDAC3 4/4885 |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC2 5/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.